Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 155
- Registration Number
- NCT00702650
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swansea, United Kingdom
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9326
- Registration Number
- NCT00699998
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunderland, United Kingdom
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: atomoxetine hydrochlorideDrug: Placebo
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2017
- Registration Number
- NCT00700427
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 79
- Registration Number
- NCT00698841
- Locations
- 🇵🇷
Local Institution, San Juan, Puerto Rico
🇺🇸Cancer Specialists Of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸Ocala Oncology Center, Ocala, Florida, United States
Switching to Duloxetine in Patients With Depression
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2010-09-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 242
- Registration Number
- NCT00696774
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
A Study for Teriparatide in Severe Osteoporosis
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 794
- Registration Number
- NCT00696644
- Locations
- 🇮🇹
For additional information regarding investigative sites for this study, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valeggio sul Mincio, Verona, Italy
A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: LY2127399Drug: Placebo
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT00689728
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
- Conditions
- Attention Deficit Hyperactivity DisorderCannabis Abuse
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT00687609
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: PemetrexedDrug: CisplatinDrug: EtoposideRadiation: Thoracic Radiation Therapy (TRT)Drug: VinorelbineDrug: PaclitaxelDrug: Carboplatin
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 598
- Registration Number
- NCT00686959
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 138
- Registration Number
- NCT00683475
- Locations
- 🇺🇸
ImClone Investigational Site, Madison, Wisconsin, United States